After signing up, you'll start to receive regular news updates from us.
Study examines association between small-vessel disease, Alzheimer pathology
Complete the form below to unlock access to ALL audio articles.
Cerebral small-vessel disease (SVD) and Alzheimer disease (AD) pathology appear to be associated.
AD is believed to be caused by the buildup of amyloid protein in the brain and tau tangles. Previous studies have suggested that SVD and vascular risk factors increase the risk of developing AD. In both SVD and vascular dementia (VaD), signs of AD pathology have been seen. But it remains unclear how the interaction between SVD and AD pathology leads to dementia.
Authors examined the association between SVD and AD pathology by looking at magnetic resonance imaging (MRI)-based microbleeds (MB), white matter hyperintensities (WMH) and lacunes (which are measures for SVD) along with certain protein levels in cerebrospinal fluid (CSF) which reflect AD pathophysiology in patients with AD, VaD and healthy control patients. The authors also examined the relationship of apolipoprotein E (APOE) ?4 genotype, a well-known risk factor for AD.
The presence of both MBs and WMH was associated with lower CSF levels of Aβ42, suggesting a direct relationship between SVD and AD. Amyloid deposits also appear to be abnormal in patients with SVD, especially in (APOE) ?4 carriers.
"Our study supports the hypothesis that the pathways of SVD and AD pathology are interconnected. Small-vessel disease could provoke amyloid pathology while AD-associated cerebral amyloid pathology may lead to auxiliary vascular damage," researchers conclude.
Note: Material may have been edited for length and content. For further information, please contact the cited source.
The JAMA Network Journals press release
Publication
Maartje I. Kester, Jeroen D. C. Goos, Charlotte E. Teunissen, Marije R. Benedictus, Femke H. Bouwman, Mike P. Wattjes, Frederik Barkhof, Philip Scheltens, Wiesje M. van der Flier. Associations Between Cerebral Small-Vessel Disease and Alzheimer Disease Pathology as Measured by Cerebrospinal Fluid Biomarkers. JAMA Neurology, Published Online May 12 2014. doi: 10.1001/jamaneurol.2014.754
